CEPT1

Across TCGA pan-cancer cohorts, CEPT1 RNA differs between tumor and matched normal tissue in 11 of 18 cancer types tested, making tumor–normal expression one of CEPT1’s most consistent transcriptional readouts.

The strongest signal is observed in bladder urothelial carcinoma (BLCA), where CEPT1 RNA is more highly expressed in tumor relative to normal tissue. In most cancer types CEPT1 is over-expressed in tumor, although a few such as THCA and LUAD show the opposite, repressed pattern.

BLCA, THCA, and LUAD are the cancer types where CEPT1 tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in CEPT1 RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
BLCA	All	III,IV	+0.706	<.001	9	view →
THCA	All	All	−0.351	<.001	8	view →
LUAD	Female	III,IV	−0.691	<.001	6	view →
STAD	All	All	+0.494	.001	6	view →
KICH	All	All	−0.813	<.001	5	view →
LUSC	All	All	−0.301	<.001	5	view →
UCEC	All	All	−0.528	.012	2	view →
KIRP	Male	All	−0.386	.014	2	view →
BRCA	All	All	−0.153	.029	2	view →
CHOL	All	All	+0.792	.006	1	view →
LIHC	Female	III,IV	+0.782	.002	1	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 11 strongest of 11 lineages.

CEPT1–BLCA

Open the BLCA breakdown →